| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 814.95 | 4.3% | 24.0% |
| Total Income | 820.50 | 4.6% | 19.9% |
| Expenditure | 588.74 | 6.0% | 12.4% |
| PBT | 231.77 | 1.1% | 44.7% |
| Net Profit | 183.33 | 1.4% | 41.4% |
| OPM | 34.55% | 0.24pp | 21.64pp |
| NPM | 22.34% | 0.69pp | 3.39pp |
| EPS | 10.96 | 1.4% | 40.5% |
IKS Health Reports 24% Q3 FY26 Revenue Growth to INR 8,150 Mn, 41% PAT Surge ended December 31, 2025
04 Feb 2026 · 4 Feb, 9:33 pm
Summary
Inventurus Knowledge Solutions Limited, a technology-enabled healthcare solutions provider, announced strong growth in Q3 FY26. IKS Health, its care enablement platform, reported robust financial results for the quarter ended December 31, 2025, with a 24% increase in revenue and a 41% surge in PAT.
Key Highlights
- 1
Q3 FY 2026 Revenue: INR 8,150 Mn, up 24% YoY and 4.3% QoQ
- 2
Q3 FY 2026 EBITDA: INR 2,816 Mn, up 40% YoY and 3.6% QoQ
- 3
Q3 FY 2026 PAT: INR 1,833 Mn, up 41% YoY and 1.4% QoQ
- 4
Q3 EBITDA Margin: 35%
- 5
Q3 PAT Margin: 22%
- 6
New partnership with StrideCare for revenue cycle management
- 7
Expanded partnership with VitalMD Group Holding and Femwell for ambient solutions
- 8
Expanded existing RCM and VBC partnership with a top 5 health system
- 9
New partnership with a risk-bearing enablement company for behavioral health system
Management Comments
Sachin K. Gupta
Founder & Global CEO, IKS Health
Our strong Q3 performance, characterized by 24% revenue growth, validates that our Care Enablement Platform is the critical solution for a US healthcare market facing a perfect storm of cost, quality, and access pressures. As physician margins face renewed compression from stagnant reimbursement rates, we are seeing this act as a powerful catalyst for increased outsourcing and platform adoption. We continue to deepen our value proposition by advancing our AI capabilities—specifically moving our Patient Engagement suite toward multi-agent orchestration—to drive cognitive reasoning and independent action.
Nithya Balasubramanian
Group CFO, IKS Health
Our Q3 FY2026 performance underscores our consistent ability to drive profitable growth and deliver significant value to our clients. We achieved a 24% year-on-year revenue increase and a 41% growth in Profit After Tax (PAT), fueled by continuous expansion across existing and new client relationships. Margin expansion is a direct result of our successful operating leverage, technology deployment and focused cost management.”
Informational and educational content only. Not investment advice.